Sierra Oncology has been granted a selection patent for its Chk1 inhibitor, SRA737 by the U.S. Patent and Trademark Office.
Sierra Oncology is a drug development company that is working to advance next generation therapeutics for patients suggering from cancer, specifically for DNA Damage Response. The patent that Sierra has been granted will provide the company with coverage until 2033 prior to any extensions taking place.
"We anticipate generating additional intellectual property claims as we advance our DDR-focused research activites and our innovative genetics-driven clinical programs," Sierra Oncology President and CEO Dr. Nick Glover said.
A European patent was issued for the same inhibitor in February.